Improvement in renal function after everolimus introduction and calcineurin inhibitor reduction in maintenance thoracic transplant recipients: the significance of baseline glomerular filtration rate

Satish Arora, Einar Gude, Vilborg Sigurdardottir, Svend Aage Mortensen, Hans Eiskjær, Gerdt Riise, Lena Mared, Oystein Bjørtuft, Bjørn Ekmehag, Kjell Jansson, Svein Simonsen, Pål Aukrust, Dag Solbu, Martin Iversen, Lars Gullestad

    50 Citationer (Scopus)

    Abstract

    The NOCTET (NOrdic Certican Trial in HEart and lung Transplantation) trial demonstrated that everolimus improves renal function in maintenance thoracic transplant (TTx) recipients. Nevertheless, introduction of everolimus is not recommended for patients with advanced renal failure. We evaluated NOCTET data to assess everolimus introduction amongst TTx recipients with advanced renal failure.
    OriginalsprogEngelsk
    TidsskriftJournal of Heart and Lung Transplantation
    Vol/bind31
    Udgave nummer3
    Sider (fra-til)259-65
    Antal sider7
    ISSN1053-2498
    DOI
    StatusUdgivet - 2012

    Fingeraftryk

    Dyk ned i forskningsemnerne om 'Improvement in renal function after everolimus introduction and calcineurin inhibitor reduction in maintenance thoracic transplant recipients: the significance of baseline glomerular filtration rate'. Sammen danner de et unikt fingeraftryk.

    Citationsformater